22056 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Hudis
    Hudis
  4. Kris
    Kris
  5. Saltz
    Saltz
  6. Offit
    Offit
  7. O'Reilly
    O'Reilly
  8. Solit
    Solit
  9. Robson
    Robson
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (22056)
  2. Department of Medicine (22034)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5183)
  6. Gastrointestinal Oncology Service (4640)
  7. Breast Medicine Service (4103)
  8. Surgery (4018)
  9. Department of Pathology and Laboratory Medicine (3422)
  10. Thoracic Oncology (3351)
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10830)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22056)
  2. Department of Medicine (22034)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5183)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22056)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: The phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Rini, B. I.; Choueiri, T. K.; Mariani, M.; Albiges, L.; Haanen, J. B.; Atkins, M. B.; Larkin, J.; Schmidinger, M.; Magazzù, D.; di Pietro, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Pre-existing immunity to oncolytic virus potentiates its therapeutic efficacy
    Meeting Abstract

    Ricca, J.; Merghoub, T.; Wolchok, J. D.; Zamarin, D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients
    Meeting Abstract

    Zappasodi, R.; Li, Y.; Qi, J.; Wong, P.; Sirard, C.; Postow, M.; Newman, W.; Koon, H.; Velcheti, V.; Callahan, M. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Exercise training reduces splenic accumulation of MDSCs and delays tumor progression in a therapeutic breast cancer model
    Meeting Abstract

    Wennerberg, E.; Schwitzer, E.; Lhuillier, C.; Koelwyn, G.; Hiner, R.; Jones, L.; Demaria, S.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
    Meeting Abstract

    Leidner, R.; Kang, H.; Haddad, R.; Segal, N. H.; Wirth, L. J.; Ferris, R. L.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T. F.; Sharfman, W.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study
    Meeting Abstract

    Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Keynote-045: Open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Missing the mark in FGFR1-amplified squamous cell cancer of the lung
    Journal Article

    Paik, P. K.; Rudin, C. M.
    Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma
    Journal Article

    Abida, W.; Milowsky, M. I.; Ostrovnaya, I.; Gerst, S. R.; Rosenberg, J. E.; Voss, M. H.; Apolo, A. B.; Regazzi, A. M.; McCoy, A. S.; Boyd, M. E.; more...
    Bladder Cancer (2016)

    Fulltext@MSK | Save